KILITCH — Kilitch Drugs (India) Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapNeutral

Annual income statement for Kilitch Drugs (India), fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	533	685	1,142	1,396	1,544
Cost of Revenue
Gross Profit	174	243	392	489	615
Selling / General / Administrative Expenses
Depreciation and Amortization
Other Operating Expenses
Total Operating Expenses	550	653	1,056	1,256	1,336
Operating Profit	-17.1	32.3	86.2	140	208
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	16.1	51.2	96.1	120	194
Provision for Income Taxes
Net Income After Taxes	8.42	37.7	62.1	82.8	136
Minority Interest
Net Income Before Extraordinary Items
Net Income	8.42	36.7	73.7	104	146
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	8.42	36.7	73.7	104	146
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.546	2.37	5.27	7.25	9.17
Dividends per Share